Next Article in Journal
Enhanced Antioxidant Capacity and Anti-Ageing Biomarkers after Diet Micronutrient Supplementation
Previous Article in Journal
Challenges and Opportunities of MicroRNAs in Lymphomas
Article Menu

Export Article

Open AccessArticle
Molecules 2014, 19(9), 14782-14793; doi:10.3390/molecules190914782

Emodin Protects against Diabetic Cardiomyopathy by Regulating the AKT/GSK-3β Signaling Pathway in the Rat Model

Department of Geriatrics, the 2nd Affiliated Hospital of Chongqing Medical University, Chongqing 400010, China
*
Author to whom correspondence should be addressed.
Received: 17 July 2014 / Revised: 18 August 2014 / Accepted: 1 September 2014 / Published: 17 September 2014
(This article belongs to the Section Medicinal Chemistry)
View Full-Text   |   Download PDF [743 KB, uploaded 17 September 2014]   |  

Abstract

Diabetes mellitus (DM) has been recognized as a major health problem. Emodin (Emo) has been reported to exhibit protective effects against diabetic nephropathy. However, little has been known about the effect of Emo on diabetic cardiomyopathy (DCM). A type 2 DM model was induced in rats by low dose streptozotocin (STZ) combined with high energy intake. We found that Emo-treated groups displayed significantly higher body weight (BW) and lower heart weight (HW)/BW. Furthermore, Emo could significantly decrease blood glucose, total cholesterol (TG) levels, and triglyceride (TC) levels in diabetic rats. Moreover, the Emo-treated group showed a marked increase in heart rate (HR) and showed lower left ventricular end-diastolic diameter (LVEDD), left ventricular end-systolic diameter (LVESD), left ventricular posterior wall thickness (LWPWT), and interventricular septal diastolic wall thickness (IVSD). Emo induced a significant increase in phosphorylation of Akt and GSK-3β in myocardium. These results suggest that Emo may have great therapeutic potential in the treatment of DCM by Akt/GSK-3β signaling pathway. View Full-Text
Keywords: emodin; diabetic cardiomyopathy; blood glucose; Akt; GSK-3β emodin; diabetic cardiomyopathy; blood glucose; Akt; GSK-3β
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Wu, Z.; Chen, Q.; Ke, D.; Li, G.; Deng, W. Emodin Protects against Diabetic Cardiomyopathy by Regulating the AKT/GSK-3β Signaling Pathway in the Rat Model. Molecules 2014, 19, 14782-14793.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]

Molecules EISSN 1420-3049 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top